Avacta appoints biotech executive and oncologist to bolster strategy

Avacta has appointed Dr Mark Goldberg as Non-executive Director to the Board with immediate effect. Dr Alastair Smith, Chief Executive Officer of Avacta, said Goldberg’s experience as a biotech executive and oncologist will greatly benefit the strategy and vision for the therapeutic business. 

Dr Goldberg is a medical oncologist and haematologist on the faculty of Brigham & Women’s Hospital and Harvard Medical School, a veteran biotech executive, and long-time American Cancer Society (ACS) and ACS Cancer Action Network (CAN) volunteer. He is the past-chair of the Eastern New England Area Board of the American Cancer Society and currently serves as a member of its national board of directors. 

Dr Goldberg commented: “I find the Affimer and pre|CISION platforms to be very innovative. I look forward to joining the Board and working with my new Board colleagues and the Avacta management team to develop novel therapies that will improve the lives of patients suffering from cancer.” 

Dr Eliot Forster, Chairman of Avacta Group, commented: “I am delighted that Mark will be joining the Board of Avacta. Mark’s wealth of experience and expertise will be invaluable as we progress our pipeline of proprietary Affimer and pre|CISION platforms into clinical stage assets.” 

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free